Search results
QRG Capital Management Inc. Sells 34,932 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)
ETF DAILY NEWS· 1 day agoQRG Capital Management Inc. cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 9.8% during the 4th quarter, ...
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss — Update
Morningstar· 7 days agoBy Kosaku Narioka Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses. The ...
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
BioPharma Dive via Yahoo Finance· 2 days agoThe deal — worth $100 million up front and potentially billions more later on — gives Takeda an...
Takeda stock down 1% as operating profit declines
Investing.com· 7 days agoTakeda Pharmaceutical (TYO: 4502 ) Company Limited (NYSE: TAK ) has surpassed its management guidance for revenue and core earnings per share (EPS) in...
Takeda Pharmaceuticals earnings: profits, EPS down over 50% in Q4 financial results | Invezz
Invezz· 6 days agoThe company described it in a press release as “a year of significant loss-of-exclusivity impact”, a...
Catalyst's New CEO Has Big Ideas For The Small Biotech
Investor's Business Daily· 5 days agoBut after cutting his teeth at Big Pharma stalwarts, including Takeda Pharmaceutical and...
Scilex reaches settlement in patent lawsuit over Gloperba By Investing.com
Investing.com· 1 day agoFederal Trade Commission and Department of Justice regarding its Settlement Agreement with Takeda ...
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Benzinga· 6 days agoOn Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited TAK announced a restructuring...
Improving the safety of iPS cell-derived pancreatic islets by eliminating unwanted cells
Medical Xpress· 2 days agoLtd., and Axcelead Drug Discovery Partners, Inc. The potential of iPS cells to become nearly any cell type in the body also creates concerns about possible risks of off-target cells...